Back to results
US 12,480,952 B2Granted
Methods of using PD-L1 expression in treatment decisions for cancer therapy
AssigneeCreatv MicroTech, Inc.
InventorsDaniel Adams, Cha-Mei Tang
Life of this patent
Estimating the term…
Abstract
Methods of using detection of PD-L1 expression by circulating cancer cells in the screening, monitoring, treatment and diagnosis of cancer in subjects are disclosed. The methods are based on assaying one or more of circulating tumor cells (CTCs), epithelial to mesenchymal transition CTCs (EMTCTCs), cancer associated macrophage-like cells (CAMLs), and cancer associated vascular endothelial cells (CAVEs) isolated from a subject having cancer for PD-L1 expression.
Claims12
A method of selecting a treatment for a subject having cancer, comprising:
- assaying cancer associated macrophage-like cells (CAMLs) and circulating tumor cells (CTCs), and optionally one or more of epithelial to mesenchymal transition CTCs (EMTCTCs) and cancer associated vascular endothelial cells (CAVEs), isolated from a subject having cancer for PD-L1 expression, wherein when PD-L1 expression is detected, the subject is identified as a subject to receive an immune checkpoint inhibitor treatment, and wherein the immune checkpoint inhibitor is an antibody.
Dependencies are inferred from the claim text.